Chokri Ben Lamine: Pathophysiology, Diagnosis and Management of Hereditary Spherocytosis
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Hereditary spherocytosis (HS) is an inherited RBC membrane disorder causing loss of membrane surface area, so RBCs become small, dense, spherical, and less deformable leading to they get trapped and destroyed mainly in the spleen.
Common culprit proteins/genes include ankyrin (ANK1), spectrin (SPTA1/SPTB), band 3 (SLC4A1), and protein 4.2 (EPB42). Most cases are autosomal dominant, and about 25% can be sporadic.
Classic clues: chronic hemolysis, anemia, jaundice, splenomegaly, reticulocytosis, and often pigment gallstones.
Severity is variable: some adults are nearly asymptomatic, while others present with symptomatic hemolysis or biliary disease.
A viral infection, especially parvovirus B19, can trigger an aplastic crisis with sudden Hb drop.
Labs / smear pearls
- Peripheral smear: spherocytes
- CBC often shows increased MCHC with reticulocytosis
- Hemolysis profile: increased indirect bilirubin, increased LDH, low haptoglobin
- DAT/Coombs is negative in HS, which helps separate it from autoimmune hemolytic anemia where spherocytes can also appear.
Diagnosis is sometimes clinical when the picture is classic: family history plus hemolysis plus spherocytes plus increased MCHC plus retics.
If the case is uncertain, useful tests include EMA binding by flow cytometry, osmotic fragility, ektacytometry, or other membrane studies.
EMA is widely used and ARUP lists a clinical sensitivity around 93%; recent transfusion can affect interpretation.
Management
- Mild/compensated HS: often observe plus monitor
- Treat acute hemolytic/aplastic crises supportively; transfuse when needed
- Watch for bilirubin gallstones and folate needs in ongoing hemolysis
- Splenectomy is the main disease-specific treatment for symptomatic hemolysis or complications such as biliary colic/persistent aplastic crises; it improves anemia and reticulocytosis but does not correct the membrane defect, so spherocytes remain.
Splenectomy pearls
- Do not rush to splenectomy unless disease burden justifies it
- Confirm the diagnosis carefully first, especially if the phenotype is atypical
- Give appropriate vaccination beforehand
- Remember lifelong concern for post-splenectomy infection, and literature also highlights concern for infectious/thrombotic complications after splenectomy.”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Mar 31, 2026, 15:43Deepak Sudheendra: When the Clot Is Gone, but Symptoms Stay
-
Mar 31, 2026, 15:15Kristopher Jonas: Why Donors Show Up and Why It All Matters
-
Mar 31, 2026, 14:50Heghine Khachatryan: Microthrombosis and the ‘Silent Brain Injury’ Paradigm
-
Mar 31, 2026, 14:39Samuele Takeshita: Scientific and Practical Aspects of Gene Therapy Access in Hemophilia and Sickle Cell Disease
-
Mar 31, 2026, 14:20Dear Thamasucharit: Why Hemostasis Testing and Bleeding Disorder Awareness Matter More Than You Think
-
Mar 31, 2026, 13:49New Researchs at ACC26 on Everyday Clinical Decisions – The Lancet Group
-
Mar 31, 2026, 12:58Akshat Jain: The Invisible Struggles of Living with Von Willebrand Disease
-
Mar 31, 2026, 12:50Emmanuele Kouvousis: DOAC Dose Adjustments for Older Patients
-
Mar 31, 2026, 12:34How Clinicians Prioritize Factors in Red Blood Cell Transfusions While Following Guidelines – AABB